Ann Thorac Surg 2006;81:297
© 2006 The Society of Thoracic Surgeons
Original article: General thoracic
Invited Commentary
Frederic Grannis, Jr, MD
Department of General and Oncologic Surgery, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010
(Email: fgrannis@coh.org).
| The first 20% of the full text of this article appears below. |
Each year 40,000 Americans present with locally advanced nonsmall cell lung cancer (NSCLC). Only a small percentage of stage IIIA and very few IIIB patients achieve long-term survival. Most research in this country concentrates on preoperative chemotherapy in stage III, whereas the contributions of pulmonary resection, mediastinal node dissection, and postoperative radiation therapy receive less attention. After the introduction of mediastinoscopy in Scandanavia in the 1950s, it became generally accepted by most American thoracic surgeons that N2 metastasis was a contraindication to primary pulmonary resection, and many publications refer . . . [Full Text of this Article]
Copyright © 2006 by The Society of Thoracic Surgeons.